Aromatase inhibition in hypogonadal older men Export

@article{citeulike:4498626, address = {Mercer University School of Pharmacy - Pharmaceutical SciencesP.O. Box 191405 Atlanta Georgia 31119 United StatesTel.: 4046333977; Fax: 4046333977E-mail: cohenpg@bellsouth.net}, author = {Cohen, Paul}, citeulike-article-id = {4498626}, citeulike-linkout-0 = {http://dx.doi.org/10.1111/j.1365-2265.2009.03566.x}, citeulike-linkout-1 = {http://www3.interscience.wiley.com/cgi-bin/abstract/122217508/ABSTRACT}, comment = {Aromatase inhibition could be an alternative to testosterone administration to mitigate declining androgen production in hypo gonadal older men. Unlike testosterone replacement, aromatase inhibition lowers circulating estradiol levels, which potentially prevents adverse effects of testosterone supplementation. Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastro zole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older) with symptoms of hypogonadism and low testo sterone levels (5.2-10.4 nmol/l in a single measure or 10.4-12.1 nmol/l in two consecutive measures). Participants were randomly assigned to receive either anastrozole 1 mg daily or placebo for 12 months; 11 men from the anastrozole group and 8 from the placebo withdrew from the study. Changes in gonadal steroid hormone levels, lower extremity strength, body composition (fat and muscle), lipid levels, prostate-specific antigen levels, and symptoms of urinary obstruction were all recorded at baseline and every 3 months thereafter. Compared with placebo and baseline measurements, aromatase inhibition increased mean serum testosterone levels by \~{}50\% at 3 months. However, mean androgen levels decreased between months 3 and 12 (but remained significantly higher than baseline), which indicated an acquired resistance to anastrozole. Conversely, anastrozole therapy lowered estradiol levels, which did not revert to baseline between months 3 and 12; no such change was observed in the placebo group. Aromatase inhibition improved testosterone levels to the mid-normal range and did not alter prostate-specific antigen levels or urinary-obstructive symptoms, but failed to improve body composition or strength.}, doi = {10.1111/j.1365-2265.2009.03566.x}, journal = {Clinical Endocrinology}, keywords = {aging, androgen, malegonadal, rct, testosterone}, number = {999A}, posted-at = {2009-05-09 19:30:06}, priority = {2}, title = {Aromatase inhibition in hypogonadal older men}, url = {http://dx.doi.org/10.1111/j.1365-2265.2009.03566.x}, volume = {9999}, year = {2009} }

TY - JOUR ID - citeulike:4498626 L3 - citeulike-article-id:4498626 IS - 999A JF - Clinical Endocrinology AD - Mercer University School of Pharmacy - Pharmaceutical SciencesP.O. Box 191405 Atlanta Georgia 31119 United StatesTel.: 4046333977; Fax: 4046333977E-mail: cohenpg@bellsouth.net TI - Aromatase inhibition in hypogonadal older men VL - 9999 KW - aging KW - androgen KW - malegonadal KW - rct KW - testosterone N1 - Aromatase inhibition could be an alternative to testosterone administration to mitigate declining androgen production in hypo gonadal older men. Unlike testosterone replacement, aromatase inhibition lowers circulating estradiol levels, which potentially prevents adverse effects of testosterone supplementation. Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastro zole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older) with symptoms of hypogonadism and low testo sterone levels (5.2-10.4 nmol/l in a single measure or 10.4-12.1 nmol/l in two consecutive measures). Participants were randomly assigned to receive either anastrozole 1 mg daily or placebo for 12 months; 11 men from the anastrozole group and 8 from the placebo withdrew from the study. Changes in gonadal steroid hormone levels, lower extremity strength, body composition (fat and muscle), lipid levels, prostate-specific antigen levels, and symptoms of urinary obstruction were all recorded at baseline and every 3 months thereafter. Compared with placebo and baseline measurements, aromatase inhibition increased mean serum testosterone levels by ~50% at 3 months. However, mean androgen levels decreased between months 3 and 12 (but remained significantly higher than baseline), which indicated an acquired resistance to anastrozole. Conversely, anastrozole therapy lowered estradiol levels, which did not revert to baseline between months 3 and 12; no such change was observed in the placebo group. Aromatase inhibition improved testosterone levels to the mid-normal range and did not alter prostate-specific antigen levels or urinary-obstructive symptoms, but failed to improve body composition or strength. AU - Cohen, Paul PY - 2009/// UR - http://dx.doi.org/10.1111/j.1365-2265.2009.03566.x ER -